Publications by authors named "T Asmis"
Introduction: The incidence of neuroendocrine tumors (NETs) is rising. Our objective was to assess trends in gastroenteropancreatic (GEP)-NETs diagnosis (June 2010 to June 2021) at TOHCC and to explore whether early COVID-19 pandemic data impacted these trends.
Methods: This was a single-center retrospective chart review of data collected from June 2010 to June 2021.
Background: Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and physical activity, along with suppressed serum GDF-15 levels.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the shift to virtual care for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) during the COVID-19 pandemic at the Ottawa Hospital Cancer Center from June 2019 to December 2022.
- - Out of 103 patients, a significant portion of follow-up visits (76.1%) and some consultations (17.5%) were conducted virtually, with a gradual return to in-person visits by 2022.
- - The findings indicate that virtual care played a major role in managing GEP-NET patients during the pandemic and suggests that it may enhance access to specialized care in the future.
Li-Fraumeni Syndrome with Unusual Synchronous Malignancies: A Case Report.
Case Rep Oncol
January 2024
Introduction: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder brought on by pathogenic mutations in the tumor suppressor gene. LFS is characterized by a high lifetime risk of developing various cancers at a relatively young age.
Case Presentation: We are presenting a 48-year-old male with a diagnosis of LFS that was confirmed by a genetic test triggered by the patient's son's diagnosis of LFS and leukemia.
Background: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy in Canadian patients with mCRC.
Materials And Methods: Retrospective data were collected in 2 waves, at least 1 year (Wave 1) or 2 years (Wave 2) after commercial availability of ABP 215 at each participating site.